Log in
Thyroid UK
100,805 members114,525 posts

Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves' Disease

Dr Simon Pearce, Professor of Endocrinology, Newcastle University, and Chief Investigator for the trial commented: "This is the first new therapy for Graves' disease to be tested in over 50 years and is a significant step forward in the development of the drug. We are very pleased to be leading the first clinical trial of ATX-GD-59 which has significant potential to treat the underlying cause of this condition for the first time."


I post previously about Newcastle university receiving £780,000 for research into Graves' Disease.


5 Replies

What wonderful news for those suffering Graves'. How completely awful that it's the first new therapy to be trialed for over fifty years. Make no mistake; misogyny is at the heart of what keeps so many thyroid patients ill. The poor men who also suffer are just collateral damage :(

Perhaps Dr Pearce has a T shirt bearing the legend ' this is what a feminist looks like'. Rock on, doc :D

1 like

Have you got any more information about how this is supposed to work? What aspect of the disease does it act on?

1 like

Sorry, I should have put the link in! Have done so now.

Apitope's ATX-GD-59 has the potential to treat and prevent the production of stimulating antibodies against TSHR (thyroid stimulating hormone receptor) that lead to Graves' disease. The Phase I trial will recruit up to 30 patients and is designed to assess the safety and initial efficacy of the product.

It's a very small trail but it's a very small amount of money but it's still uplifting. :-)


No, not at the moment. He did say that it would be one tablet for several months rather than daily. People can contact them for more info.


Literally crying with happiness about this!!!!!!

1 like

You may also like...